Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPL7L1P9 is a processed pseudogene in the human genome named "ribosomal protein L7 like 1 pseudogene 9" and abbreviated as RPL7L1P9[5]. Pseudogenes such as RPL7L1P9 result from duplication or retrotransposition of ancestral ribosomal protein genes but have lost the ability to encode functional proteins[5]. Unlike protein-coding ribosomal proteins (such as RPL7, which is involved in ribosome structure and protein synthesis[1]), RPL7L1P9 does not have established molecular or cellular functions, and there are no reports of its involvement in disease, drug interaction, or use as a biomarker or therapeutic target. There is increasing interest in certain ribosomal pseudogenes for possible regulatory roles in immunity or cancer, but no specific functional data for RPL7L1P9 is available[2].
None (No described mechanism for drug action on this pseudogene)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L7 like 1 pseudogene 9 (RPL7L1P9).